Magdalena Emilia Kulas

Biosimilars are no longer the quiet corner of Pharma. The European Commission has just approved USYMRO® (ustekinumab), Bio-Thera’s Stelara® biosimilar, to be commercialized by Gedeon Richter in Europe. On the surface, another biosimilar launch. But look closer: Richter is reinventing itself. Once a “generics-first” company, it now mixes CNS royalties, women’s health innovation, and a growing biologics arm. Asset-light strategy. Bio-Thera builds and manufactures; Richter focuses on what it does best, commercial execution. Pipeline stacking. Denosumab, tocilizumab, teriparatide, and now ustekinumab, a steady cadence of launches. It has become clear that the biosimilar space is getting crowded: Sandoz, Amgen, Samsung, Biocon, Celltrion, Stada, and now Chinese players all chasing the same off-patent biologics. Discounts deepen, margins tighten. Can smart partnering and commercial muscle beat pure scale? Richter’s bet is yes… and USYMRO® will be a test case. 🔔 Follow for insights  ♻️ Share if you find it interesting #biosimilars #pharma #generics #strategy

256

6 komentarzy

I'm thrilled to share that Lupin has entered into a strategic license and supply agreement with Zentiva Group, a leading pan-European pharmaceutical company, for the global commercialization of our biosimilar Certolizumab Pegol. 🤝 This collaboration brings together Lupin’s strong development and manufacturing capabilities with Zentiva’s robust commercial infrastructure across Europe and the CIS region. Lupin will continue to lead commercialization efforts in other key markets, including the U.S. and Canada. 💡 Together, we aim to expand access to high-quality, affordable biosimilar therapies for patients around the world.

303

23 komentarze

Following the go-live of Teva’s Gx Health Check 3.0 and strong media interest across the EU, including my home country Poland, we hope to drive action for stronger policy measures—especially with the Critical Medicines Act coming next week. Europe’s medicine supply is under pressure and the report highlights growing challenges in ensuring the availability of critical generic medicines—challenges that require urgent policy action.   At Teva, we support key measures to reinforce Europe’s medicines supply:   Preventing supply disruptions with a European Solidarity Mechanism and regulatory flexibilities like digital leaflets and harmonized packaging. Ensuring sustainability through stronger procurement models and impact assessments to avoid unintended disruptions. Boosting manufacturing with investment-friendly policies and expanded “first-of-a-kind” facility definitions for sustainable API production.   Collaboration between industry and policymakers is crucial. The time to act is now.   https://lnkd.in/gN7eXfYS   #tevapharm #tevapharmceuticals #medicinessuppy #suppy #gx #generics #criticalmedicines #patient #access #accesstomedicines #policy #healthcare #GxHealthCheck #HCC2025

59

2 komentarze

Patient recruitment remains one of the toughest hurdles in clinical research. In this short video, our Senior CRA, Tihomira Leteyski, shares five practical strategies we use at Cromos Pharma to help sites overcome key barriers—from strict eligibility criteria to underused referral networks. Watch the full video to see how a proactive, site-focused approach can accelerate enrollment. #PatientRecruitment #ClinicalTrials #ClinicalResearch #CRO #CromosPharma

26

1 komentarz